Minerva Neurosciences (NERV) AI Stock Analysis

• Market Cap: $285.61M
• Dividend Yield: N/A
• Average Volume (3M): 465.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.13
• Revenue Growth: N/A
• EPS Growth: -323.61%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.36
• Shares Outstanding: 43,274,400
• 10 Day Avg. Volume: 1,362,901
• 30 Day Avg. Volume: 465,600
• PEG Ratio: -0.11
• Price to Book (P/B): -0.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.86
• Enterprise Value/Market Cap: 0.12
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -24.88K
• Enterprise Value/Ebitda: -3.30
• 1Y Price Target: $4.50
• Price Target Upside: -31.82% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.54
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $5.00 ▼(-24.24% Downside)
• Action: Reiterated Date: 02/04/26
• Date: Action: Reiterated 02/04/26

The score is held down primarily by weak financial performance (limited recurring revenue, ongoing operating losses, persistent cash burn, and negative equity). Offsetting this, technicals show strong upward trend/momentum, and corporate updates support continued pipeline advancement and financing flexibility, though valuation remains hard to justify with negative earnings and no dividend.

Positive Factors

Confirmatory Phase 3 plan for roluperidone

A defined, timely Phase 3 program and clear endpoints materially reduce development uncertainty versus undefined plans. A 380-patient randomized design and explicit readout milestones create a concrete path to regulatory decision, partner interest, and long-term value creation if results are positive.

$200M fundraising and board expertise

A recent sizable capital raise plus onboarding of an experienced drug-development director/consultant increases the likelihood of executing a complex Phase 3. Structural benefits include extended runway, enhanced trial design capability, and stronger credibility with partners and regulators.

Minimal reported debt

Very low debt lowers fixed financial obligations and interest burden, preserving flexibility to finance R&D through equity or partnerships. For a cash-burning clinical-stage biotech, limited leverage reduces insolvency risk during multi-year development programs.

Negative Factors

Negative shareholders' equity

Sustained negative equity and shrinking assets signal balance-sheet deterioration that limits financial flexibility. This structural weakness can hinder non-dilutive financing, raise borrowing costs, and reduce strategic optionality if development timelines extend or outcomes are delayed.

Persistent negative operating and free cash flow

Continuous cash burn requires recurrent capital raises or partner funding, creating dilution risk and potential program prioritization decisions. Structurally, negative OCF/FCF undermines sustainability absent commercial revenue and makes long-term planning dependent on external financing conditions.

Lack of recurring revenue

As a development-stage company with no commercial products, Minerva relies on financings and partnerships. This structural revenue absence concentrates enterprise value in trial outcomes for one lead asset, increasing binary outcome risk and operational vulnerability if trials fail or are delayed.

Minerva Neurosciences Business Overview & Revenue Model

Company Description

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Minerva Neurosciences makes money through the development and potential future commercialization of its proprietary drug candidates, which are aimed at treating central nervous system disorders. The company seeks to advance its drug candidates through clinical trials, obtain regulatory approval, and eventually bring these therapies to market. Revenue generation is expected to come from product sales, licensing agreements, and strategic partnerships with other pharmaceutical companies. However, as a clinical-stage company, Minerva Neurosciences currently does not have significant revenue from product sales and relies on funding through public and private investments to support its research and development activities.

Minerva Neurosciences Financial Statement Overview

Summary

Overall financial strength is weak for a development-stage biotech: revenue is largely absent/inconsistent, operating losses persist, and operating/free cash flow are negative every year (ongoing cash burn). While debt appears minimal, negative equity (2022–2024) and declining assets reduce balance-sheet flexibility.

Income Statement

Revenue has been inconsistent (zero in most years, with a one-time revenue year in 2020), which limits visibility into an ongoing commercial base. Profitability is weak: operating losses persist from 2021–2024 (negative EBIT each year), although 2024 reported positive net income despite continued operating losses, suggesting non-operating items rather than core earnings strength. Overall, the income profile reflects a development-stage biotech with high expense load and limited recurring revenue.

Balance Sheet

Reported debt is minimal to none, which reduces financial leverage risk. However, stockholders’ equity is negative in 2022–2024, signaling balance-sheet strain and reduced financial flexibility, and total assets have declined materially from earlier periods (e.g., from 2021/2019 levels to 2024). The combination of shrinking assets and negative equity is a key weakness despite the low debt.

Cash Flow

Cash generation is a major pressure point: operating cash flow and free cash flow are negative in every year shown, indicating ongoing cash burn. Free cash flow deterioration in 2024 versus 2023 (negative growth) highlights worsening near-term cash usage, even though burn improved versus 2022. With persistent negative free cash flow, funding needs likely remain elevated unless expenses decline or sustainable revenue returns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	41.18M
Gross Profit	-1.36K	0.00	0.00	0.00	0.00	41.18M
EBITDA	-10.27M	6.02M	-21.69M	-24.69M	-45.28M	2.12M
Net Income	-10.27M	1.44M	-30.01M	-32.11M	-49.91M	1.94M
Balance Sheet
Total Assets	28.09M	37.14M	56.90M	55.09M	77.12M	57.63M
Cash, Cash Equivalents and Short-Term Investments	12.29M	21.36M	40.91M	36.09M	60.76M	25.36M
Total Debt	0.00	0.00	0.00	0.00	0.00	111.23K
Total Liabilities	62.67M	62.84M	85.36M	75.11M	69.15M	4.96M
Stockholders Equity	-34.58M	-25.69M	-28.46M	-20.02M	7.98M	52.66M
Cash Flow
Free Cash Flow	-10.13M	-19.55M	-14.78M	-24.66M	-24.60M	-33.82M
Operating Cash Flow	-10.13M	-19.55M	-14.78M	-24.65M	-24.60M	-33.82M
Investing Cash Flow	0.00	0.00	0.00	-16.33K	0.00	24.53M
Financing Cash Flow	-45.17K	0.00	19.60M	-5.00	60.00M	13.24M

Minerva Neurosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NERV, the sentiment is Positive. The current price of 6.6 is above the 20-day moving average (MA) of 5.65, above the 50-day MA of 4.76, and above the 200-day MA of 3.08, indicating a bullish trend. The MACD of 0.51 indicates Positive momentum. The RSI at 67.11 is Neutral, neither overbought nor oversold. The STOCH value of 55.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NERV.

Minerva Neurosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NERV	54 Neutral	$285.61M	-3.56	―	―	―	-323.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLRX	48 Neutral	$12.49M	-2.07	-22.03%	―	-41.76%	87.36%
PULM	48 Neutral	$10.92M	-2.12	-79.47%	―	-99.97%	35.59%
CMMB	39 Underperform	$11.45M	-1.00	-73.63%	―	―	53.19%

Minerva Neurosciences Corporate Events

Minerva Outlines Confirmatory Phase 3 Plan for Roluperidone

Minerva Neurosciences announced that at a virtual key opinion leader event held on February 3, 2026, it would provide additional details on its proposed confirmatory Phase 3 trial of roluperidone for the treatment of negative symptoms in schizophrenia. The company outlined plans to initiate the trial in the second quarter of 2026, enrolling 380 patients randomized to receive either placebo or a once-daily 64 mg dose of roluperidone, with a primary efficacy endpoint based on change from baseline in PANSS Marder negative symptoms factor score at 12 weeks, followed by a 40-week relapse assessment phase in which patients will crossover to receive either roluperidone or antipsychotics, with topline efficacy data expected in the second half of 2027 and relapse assessment results anticipated in the second half of 2028, underscoring Minerva’s continued effort to advance a potential first-in-class treatment for an area of significant unmet need in schizophrenia care.

The most recent analyst rating on (NERV) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Minerva Neurosciences stock, see the NERV Stock Forecast page.

Minerva Neurosciences Shareholders Approve Key Governance Measures

At its annual meeting of stockholders held on December 22, 2025, Minerva Neurosciences, Inc. secured broad shareholder approval for a series of measures expanding its equity and capital flexibility, including an amendment to its 2013 Equity Incentive Plan to add 12,500,000 shares for potential issuance. Stockholders re-elected two directors to terms running until the 2028 annual meeting, approved doubling the company’s authorized common shares from 125 million to 250 million, authorized the issuance of common stock upon conversion of Series A Convertible Voting Preferred Stock in line with Nasdaq rules, endorsed executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2025, collectively reinforcing management’s governance, financing capacity and incentive structures.

The most recent analyst rating on (NERV) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Minerva Neurosciences stock, see the NERV Stock Forecast page.

Minerva Neurosciences Expands Board Amid Fundraising Effort

On November 14, 2025, Minerva Neurosciences appointed Dr. Inderjit Kaul to its Board of Directors as part of an expansion following a securities purchase agreement. Dr. Kaul, who brings extensive experience in drug development, will also serve as a consultant to assist with the clinical development of roluperidone, a treatment for negative symptoms of schizophrenia. This appointment aligns with Minerva’s recent $200 million fundraising effort to support a Phase 3 trial of roluperidone, aiming to address a significant unmet need in schizophrenia treatment.

The most recent analyst rating on (NERV) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Minerva Neurosciences stock, see the NERV Stock Forecast page.